Inflammation: How Much Is Too Much and Can It Be Controlled?

[1]  Masatoshi Suzuki,et al.  Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion , 1998, The Journal of experimental medicine.

[2]  M. Schultzberg,et al.  Effects of Peripheral Administration of LPS on the Expression of Immunoreactive Interleukin‐1α, β, and Receptor Antagonist in Rat Brain , 1998 .

[3]  A. Mantovani,et al.  Regulation of Inhibitory Pathways of the Interleukin‐1 System , 1998, Annals of the New York Academy of Sciences.

[4]  C. Lang,et al.  Role of central IL-1 in regulating peripheral IGF-I during endotoxemia and sepsis. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  E. Abraham.  Cytokine modifiers: pipe dream or reality? , 1998, Chest.

[6]  H. Shimauchi,et al.  Balance of interleukin-1 beta and interleukin-1 receptor antagonist in human periapical lesions. , 1998, Journal of endodontics.

[7]  J. May.  Surgery: Scientific principles and practice , 1997 .

[8]  H. Matsuyuki,et al.  Effects of nonsteroidal anti-inflammatory drugs on interleukin-1 receptor antagonist production in cultured human peripheral blood mononuclear cells. , 1997, Prostaglandins.

[9]  G. Wakabayashi,et al.  Anti-inflammatory cytokine levels in patients with septic shock. , 1997, Research communications in molecular pathology and pharmacology.

[10]  G. Slotman,et al.  Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. , 1997, Annals of surgery.

[11]  M. Davies,et al.  Systemic inflammatory response syndrome , 1997, The British journal of surgery.

[12]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[13]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[14]  C. Gabay,et al.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. , 1997, The Journal of clinical investigation.

[15]  F. Cominelli,et al.  Interleukin-1 receptor antagonist: a "novel" acute phase protein with antiinflammatory activities. , 1997, The Journal of clinical investigation.

[16]  H. Bruining,et al.  p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. , 1997, JAMA.

[17]  H. Bruining,et al.  p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial , 1997 .

[18]  A. Matsukawa,et al.  Detection and characterization of IL-1 receptor antagonist in tissues from healthy rabbits: IL-1 receptor antagonist is probably involved in health. , 1997, Cytokine.

[19]  P. Parsons,et al.  Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. , 1997, American journal of respiratory and critical care medicine.

[20]  M. Kitajima,et al.  Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. , 1997, Transplantation.

[21]  J. Kavanagh,et al.  Kinetics of circulating TNF-alpha and TNF soluble receptors following surgery in a clinical model of sepsis. , 1996, Cytokine.

[22]  C. Marsh,et al.  The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra). , 1996, Cytokine.

[23]  R. Bone,et al.  Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.

[24]  D. Colagiovanni,et al.  Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance. , 1996, Immunopharmacology and immunotoxicology.

[25]  J. Steer,et al.  Dexamethasone Antagonizes IL-4 and IL-10-Induced Release of IL-IRA by Monocytes but Augments IL-4-, IL-10-, and TGF-β-Induced Suppression of TNF-α Release , 1996 .

[26]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[27]  S. Willatts,et al.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.

[28]  E. Vizi,et al.  Cytokine production and its manipulation by vasoactive drugs. , 1996, New horizons.

[29]  S. Lowry,et al.  Biologic Control of Injury and Inflammation: Much More than Too Little or Too Late , 1996, World Journal of Surgery.

[30]  P. Barie,et al.  Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. , 1996, Archives of surgery.

[31]  J. Cavaillon,et al.  IL-10 and IL-4 synergize with TNF-α to induce IL-1ra production by human neutrophils , 1996 .

[32]  J. Dhainaut,et al.  CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. , 1995, Critical care medicine.

[33]  L. Moldawer,et al.  Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses , 1995, The Journal of experimental medicine.

[34]  A. Okken,et al.  Increased Plasma Concentrations of Interleukin-1 Receptor Antagonist in Neonatal Sepsis , 1995, Pediatric Research.

[35]  Alfred Ayala,et al.  Effects of hydroxyethyl starch after trauma-hemorrhagic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6 levels. , 1995, Critical care medicine.

[36]  A. Gwosdow.  Mechanisms of interleukin-1-induced hormone secretion from the rat adrenal gland. , 1995, Endocrine research.

[37]  S. Lowry,et al.  An overview of mortality risk prediction in sepsis. , 1995, Critical care medicine.

[38]  R. Sauerwein,et al.  Circulating interleukin-6 receptor in patients with sepsis syndrome. , 1995, The Journal of infectious diseases.

[39]  T. van der Poll,et al.  Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood , 1994, Infection and immunity.

[40]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[41]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[42]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[43]  D. Banner,et al.  Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.

[44]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[45]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[46]  R. Clark.  Basics of cutaneous wound repair. , 1993, The Journal of dermatologic surgery and oncology.

[47]  J. Cohen,et al.  Observations on the role of tumor necrosis factor‐α in a murine model of shock due to Streptococcus pyogenes , 1993, Critical care medicine.

[48]  S. Calvano,et al.  Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. , 1993, Journal of immunology.

[49]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[50]  A. Chang,et al.  Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. , 1992, The Journal of trauma.

[51]  R. Tompkins,et al.  Circulating interleukin‐1β and tumor necrosis factor‐α concentrations after burn injury in humans , 1992 .

[52]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Remick,et al.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.

[54]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[55]  L. Moldawer,et al.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. , 1992, Blood.

[56]  L. Tartaglia,et al.  Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. , 1992, Journal of Biological Chemistry.

[57]  J. Vincent,et al.  Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. , 1992, Chest.

[58]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[59]  J. Halgunset,et al.  Cytokine-associated tissue injury and lethality in mice: a comparative study. , 1991, Clinical immunology and immunopathology.

[60]  I. Chaudry,et al.  Diltiazem restores IL-2, IL-3, IL-6, and IFN-gamma synthesis and decreases host susceptibility to sepsis following hemorrhage. , 1991, The Journal of surgical research.

[61]  J. Norton,et al.  The Local Effects of Cachectin/Tumor Necrosis Factor on Wound Healing , 1991, Annals of surgery.

[62]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[63]  D. Dripps,et al.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.

[64]  J. Norton,et al.  A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.

[65]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[66]  A. Ray,et al.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion , 1990, Molecular and cellular biology.

[67]  I. Chaudry,et al.  Hemorrhage and resuscitation: immunological aspects. , 1990, The American journal of physiology.

[68]  A. Cerami,et al.  Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. , 1990, The Journal of clinical investigation.

[69]  T. Standiford,et al.  Host responses in mediating sepsis and adult respiratory distress syndrome. , 1990, Seminars in respiratory infections.

[70]  S. Akira,et al.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  Jiahuai Han,et al.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway , 1990, The Journal of experimental medicine.

[72]  E. O. Johnson,et al.  Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. , 1990, Endocrinology.

[73]  J. Gauldie,et al.  IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. , 1990, Journal of immunology.

[74]  D. Williams,et al.  Beneficial effect of enhanced macrophage function in the trauma patient. , 1990, Annals of surgery.

[75]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[76]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[77]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[78]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[79]  O. Ramilo,et al.  Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. , 1989, The Journal of pediatrics.

[80]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[81]  L. Moldawer,et al.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. , 1989, Journal of immunology.

[82]  K. Tracey,et al.  Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. , 1989, The American journal of physiology.

[83]  S. Zuckerman,et al.  Differential regulation of lipopolysaccharide‐induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary‐adrenal axis , 1989, European journal of immunology.

[84]  B. Schleiffenbaum,et al.  Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. , 1989, The Journal of clinical investigation.

[85]  P. Heinrich,et al.  Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.

[86]  K. Tracey,et al.  Cachetin/TNF-α in Septic Shock and Septic Adult Respiratory Distress Syndrome , 1988 .

[87]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[88]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[89]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[90]  R. Sapolsky,et al.  Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. , 1987, Science.

[91]  M. Lumpkin.  The regulation of ACTH secretion by IL-1. , 1987, Science.

[92]  H. Besedovsky,et al.  Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. , 1987, Science.

[93]  J. Holaday,et al.  Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. , 1987, Science.

[94]  F. Bauss,et al.  Tumor necrosis factor mediates endotoxic effects in mice , 1987, Infection and immunity.

[95]  D. Remick,et al.  Acute in vivo effects of human recombinant tumor necrosis factor. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[96]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[97]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[98]  F. Breviario,et al.  Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. , 1986, Biochemical and biophysical research communications.

[99]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[100]  K. Hajjar,et al.  Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor , 1986, The Journal of experimental medicine.

[101]  D. Stern,et al.  Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[102]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[103]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.

[104]  K. Werdan,et al.  Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. , 1998, Blood.

[105]  R. Read.  Experimental therapies for sepsis directed against tumour necrosis factor. , 1998, The Journal of antimicrobial chemotherapy.

[106]  P. Nyström,et al.  The systemic inflammatory response syndrome: definitions and aetiology. , 1998, The Journal of antimicrobial chemotherapy.

[107]  M. Yoshida,et al.  Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns. , 1996, Journal of medicine.

[108]  R. Bone,et al.  Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. , 1996, Critical care medicine.

[109]  J. Vincent,et al.  Interleukin-10 as a protective cytokine produced during sepsis , 1996 .

[110]  F. Holsboer,et al.  Inhibition of lipopolysaccharide-induced monocyte interleukin-1 receptor antagonist synthesis by cortisol: involvement of the mineralocorticoid receptor. , 1996, The Journal of clinical endocrinology and metabolism.

[111]  Cavaillon Jm.  Cytokines in inflammation , 1995 .

[112]  M. Goldman,et al.  High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. , 1995, The Journal of infectious diseases.

[113]  B. Ryffel,et al.  TNF receptor distribution in human tissues. , 1993, International Review of Experimental Pathology.

[114]  P. Ghezzi,et al.  Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. , 1993, European cytokine network.

[115]  S. Hofbauer,et al.  Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. , 1992, Scandinavian journal of infectious diseases.

[116]  J. Murray,et al.  Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. , 1990, The American review of respiratory disease.

[117]  A. Pines,et al.  High-resolution 27AI NMR spectroscopy of the aluminophosphate molecular sieve VPI-5 , 1990, Nature.

[118]  R. Strieter,et al.  Mechanisms that regulate the production and effects of tumor necrosis factor-alpha. , 1989, Critical reviews in immunology.